SYNTHESIS OF (±)-PROSURUGATOXIN AND RING TRANSFORMATION OF PROSURUGATOXIN INTO SURUGATOXIN

Shoji Inoue,<sup>\*</sup> Kunisuke Okada, Hideo Tanino, and Hisae Kakoi Faculty of Pharmacy, Meijo University, Tenpaku, Nagoya 468, Japan

Summary: Synthetic identification of prosurugatoxin and data indicating a possible mechanism for the ring transformation of prosurugatoxin into surugatoxin are presented.

Neosurugatoxin  $\underline{1}, \underline{1}$  isolated from the toxic Japanese ivory shell, <u>Babylonia japonica</u>, by Kosuge and Tsuji et al. in 1981, is a causative agent of intoxication following ingestion of the toxic shell. This toxin accounts for half the total toxicity of the shell. In 1985, the Kosuge group isolated a new toxic component from the same toxicated shell which accounts for the remaining toxicity of the above shell.<sup>2)</sup> From spectral data and the skeletal conversion of this new toxin into a non-toxic compound of surugatoxin  $\underline{2}, \underline{3}$  its structure was determined to be the de-xylopyranosyl neosurugatoxin shown in structure  $\underline{3}^{2}$  and designated  $\underline{3}$  as prosurugatoxin.

The present authors succeeded in synthesizing 3, starting from carboxylic acid  $4,^{4}$  the aglycone of both neosurugatoxin 1 and prosurugatoxin 3. This paper provides confirmation of the structure of 3 as prosurugatoxin and presents a possible mechanism for the ring transformation of 3 into Aglycone  $\underline{4}$ , prepared from 6-bromoisatin and methylthioethyl surugatoxin 2. 4-phthalimidoacetoacetate in 13 steps as reported in our previous paper,<sup>4)</sup> was esterified with (±)-2,3-cyclohexylidene-4,5-isopropyridene-1-0methoxymethyl-myo-inositol<sup>5</sup>) (1.2 equiv) in the presence of picryl chloride (step-wise addition, 3.6 equiv) in pyridine at room temperature for 1 hr to give the desired ester 5 as a mixture of diastereoisomers subsequently separated by repeated silica gel TLC [i] MeOH-CH<sub>2</sub>Cl<sub>2</sub>=1:50, ii) THF-nhexane=3:8; more polar isomer 5A, 6 11.6%, less polar isomer 5B, 7 21.1%]. As in the synthesis of neosurugatoxin, 4) 5A gave natural prosurugatoxin 3 by the following procedure. Hydrolysis of 5A with 0.1N KOH in MeOH under nitrogen atmosphere (rt, 45 min) followed by heating a mixture of the resulting deacetylated products  $\underline{6}$  with a large amount of AcONa (20 equiv, 60°C, 30 min) in MeOH gave an equilibrium mixture of four stereoisomeric prosurugatoxin derivatives  $\underline{6}$  ( $\underline{6}a-d$ , separated by silica gel TLC: i) MeOH-CH<sub>2</sub>Cl<sub>2</sub>=1:20, ii) AcOEt-benzene=3:2). Since the NMR spectrum of 6b<sup>8)</sup> was consistent with that of the natural form, it was collected by recycling the recovered unnatural three isomers 6a, 6c, and 6d [total yield of 6b for five runs, 70% (corrected)]. Treatment of 6b with 90% TFA (rt, 45 min) provided (±)-3 in 75% yield, whose structure was clearly confirmed by comparing its



- $\frac{1}{R} : neosurugatoxin \\ Ho \qquad OH \\ R = OH$
- 3 : prosurugatoxin

R = H



5 ( A, B : diastereoisomers )

Scheme I



2 : surugatoxin



<u>2</u> : surugatoxin





stereoisomers at C<sup>\*</sup> )

chromatographical (HPLC: Develosil ODS-5, 30% MeOH in  $H_2O$ ) and spectral (<sup>1</sup>H-NMR, SIMS, UV) data with those of natural prosurugatoxin <u>3</u>.<sup>2</sup>)

The mydriasis activity of synthetic  $(\pm)-\underline{3}$  was about half that of natural prosurugatoxin while the activity of the diastereoisomer of  $(\pm)-\underline{3}$ , prepared from <u>5B</u> by the same method as for <u>5A</u>, was essentially the same as that of  $(\pm)$ -prosurugatoxin <u>3</u>. Thus, mydriasis is not influenced by its stereochemical difference with the myo-inositol ester moiety in <u>3</u>.

 $(\pm)$ -Prosurugatoxin 3 thus obtained is fairly unstable in DMSO at room temperature for isomerizing a mydriasis active product considered to be the  $C_1$ -epimer of (±)-3.<sup>9)</sup> When a solution of prosurugatoxin 3 in 1% acetic acid was kept for a few days at room temperature, an interesting ring transformation occurred, leading to a mydriasis inactive compound identified as surugatoxin 2. An attempt was then made to clarify the mechanism of this novel phenomenon as follows: a solution of  $(\pm)-3$  (1 mg) in 1% acetic acid (3 ml) was introduced into a cylinder filled with  $^{18}O_2$  (100 ml, 1 atom) followed by stirring at room temperature. After two days, the reaction was stopped and the mixture was separated by HPLC (Develosil ODS-5, 30% MeOH in H2O) into the following three fractions : surugatoxin 2 (40%), C<sub>1</sub>-epimer of prosurugatoxin 3 (7%), and prosurugatoxin 3 recovered (45%). Surugatoxin 2 was analyzed by its mass spectrum (SIMS: m/z 690, 688 (MH<sup>+</sup>), which clearly indicated the presence of two atoms of 180 in its molecule. The positions of these oxygens should be  $C_4$  and  $C_6$  in 2. Actually, the mass spectrum of the dehydrated derivative, readily available from  $^{18}$ O-labeled <u>2</u> with 90% TFA (60°C, 1 hr), indicated the absence of an  $^{18}$ O atom at the C<sub>4</sub>-position in <u>2</u>. Thus, <sup>18</sup>0-labelling experiments demonstrate this novel ring transfromation of 3 into 2 to occur stereospecifically via a ten-membered lactam intermediate where it is generated in situ by decomposition of an intermediate dioxetane formed by autoxidation of the imine moiety of 3 (scheme I).

<u>Acknowledgements</u>: We thank Professors T. Kosuge and K. Tsuji for generous gift of natural prosurugatoxin and its spectral data.

## References and Notes:

 T. Kosuge, K. Tsuji, K. Hirai, K. Yamaguchi, T. Okamoto, and Y. Iitaka, Tetrahedron Lett., <u>22</u>, 3417 (1981).

T. Kosuge, K. Tsuji, and K. Hirai, Chem. Pharm. Bull., 30, 3255 (1982).

- T. Kosuge, K.Tsuji, K. Hirai, T.Fukuyama, H. Nukaya, and H. Ishida, Chem. Pharm. Bull., <u>33</u>, 2890 (1985).
- T. Kosuge, H. Zenda, A. Ochiai, N. Masaki, M. Noguchi, S. Kimura, and H. Narita, Tetrahedron Lett., 2545 (1972).

- S. Inoue, K. Okada, H. Tanino, and H. Kakoi, Tetrahedron Lett., <u>27</u>, 5225 (1986).
- 5) S. Inoue, K. Okada, H. Tanino, K. Hashizume, and H. Kakoi, Tetrahedron Lett., <u>25</u>, 4407 (1984) and references cited therein.
- 6) PMR (400 MHz, CDCl<sub>3</sub>) δ: 1.32(3H, s), 1.36(3H, s), 1.53(3H, s),1.20-1.74(10H, m), 2.02(3H, s), 2.62(3H, s), 2.87(1H, dd, J=10.7, 7.8 Hz), 3.33(3H, s), 3.47(1H, dd, J=3.7, 2.4 Hz), 3.49(1H, ddd, J=12.0, 7.8, 1.5 Hz), 3.68(1H, ddd, J=11.0, 7.8, 2.9 Hz), 3.73(1H, dd, J=7.3, 3.7 Hz), 3.84(1H, d, J=11.0 Hz), 4.01(1H, ddd, J=12.0, 7.3, 2.9 Hz), 4.03(1H, dd, J=10.7, 7.3 Hz), 4.16(1H, t, J=7.3 Hz), 4.57 and 4.65(2H, d of AB, J=6.6 Hz), 4.95(1H, dd, J=7.8, 2.4 Hz), 5.35(2H, s), 5.41 and 5.49(2H, d of AB, J=13.2 Hz), 5.80(1H, br dd, J=7.3, 1.5 Hz), 6.99(1H, d, J=8.1 Hz), 7.24-7.50(11H, m), 8.52(1H, d, J=2.0 Hz).
- 7) PMR (400 MHz, CDCl<sub>3</sub>) δ: 1.36(3H, s), 1.38(3H, s), 1.51(3H, s), 1.50-1.72(10H, m), 2.01(3H, s), 2.60(3H, s), 2.88(1H, dd, J=10.6, 8.4 Hz), 3.36 (3H, s), 3.46(1H, t, J=3.0 Hz), 3.51(1H, ddd, J=12.1, 7.7, 1.5 Hz), 3.65(1H, ddd, J=10.6, 7.7, 2.8 Hz), 3.77(1H, dd, J=7.0, 3.0 Hz), 3.81(1H, d, J=10.6 Hz), 4.03(1H, dd, J=10.6, 7.0 Hz), 4.05(1H, ddd, J=12.1, 7.3, 2.8 Hz), 4.17(1H, t, J=7.0 Hz), 4.60 and 4.68(2H, d of AB, J=6.6 Hz), 4.97(1H, dd, J=8.4, 3.0 Hz), 5.35(2H, s), 5.40 and 5.49(2H, d of AB, J=13.2 Hz), 5.82(1H, br dd, J=7.3, 1.5 Hz), 6.96(1H, d, J=8.1 Hz), 7.22-7.48(11H, m), 8.52(1H, d, J=1.8 Hz).
- 8) PMR (400 MHz, CDCl<sub>3</sub>) &: 1.33(3H, s), 1.36(3H, s), 1.41(3H, s), 1.50-1.80(10H, m), 2.93(1H, dd, J=10.6, 8.1 Hz), 3.03(1H, d, J=10.3 Hz), 3.26(1H, ddd, J=12.1, 9.5, 1.0 Hz), 3.36(3H, s), 3.46(1H, dd, J=3.7, 2.6 Hz), 3.79(1H, dd, J=7.3, 3.7 Hz), 3.89(2H, m), 4.02(1H, dd, J=10.6, 7.3 Hz), 4.17(1H, t, J=7.3 Hz), 4.24(1H, br s), 4.63 and 4.67(2H, d of AB, J=6.6 Hz), 5.04(1H, dd, J=8.1, 2.6 Hz), 5.33(2H, s), 5.40 and 5.44(2H, d of AB, J=12.5 Hz), 5.90(1H, br dd, J=6.6, 1.0 Hz), 7.05(1H, d, J=1.8 Hz), 7.06(1H, d, J=8.1 Hz), 7.20(1H, dd, J=8.1, 1.8 Hz), 7.24-7.48(10H, m), 8.17(1H, s).
- 9) PMR (300 MHz,  $D_2O$ , DOH=4.65 ppm)  $\delta$ : 1.09(3H,s), 2.93(1H, t, J=9.6 Hz), 3.26(1H, dd, J=9.6, 3.1 Hz), 3.25-3.35(2H, m), 3.46(1H, t, J=9.6 Hz), 3.40-3.53(1H, m), 3.79(1H, d, J=10.5 Hz), 3.85(1H, t, J=3.1 Hz), 3.93(1H, dd, J=13.1, 2.6 Hz), 4.81(1H, t, J=9.6 Hz), 7.17(1H, d, J=1.8 Hz), 7.22(1H, dd, J=8.1, 1.8 Hz), 7.27(1H, d, J=8.1 Hz).

The structural proof and the biological properties of this compound will be reported elsewhere.

(Received in Japan 21 December 1987)